Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...
Political uncertainty, especially with Trump’s election, has also made investors nervous. In 2024, Novo Nordisk A/S (NYSE:NVO) raised its total dividend per share by 21.3% to DKK 11.40 ...
Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 18 unusual trades. Delving into the details, we found 33 ...
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...
It has been about 100 years since Novo Nordisk marketed the first effective drug for diabetes, and although tremendous progress has been made, the Danish company is never fully satisfied.
Novo Nordisk announced on Wednesday that it will conduct additional trials for its next-generation obesity drug candidate, CagriSema. The new trials will explore dose escalation and trial length to ...
Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for … ...
Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback